JP2024113096A5 - - Google Patents

Download PDF

Info

Publication number
JP2024113096A5
JP2024113096A5 JP2024091837A JP2024091837A JP2024113096A5 JP 2024113096 A5 JP2024113096 A5 JP 2024113096A5 JP 2024091837 A JP2024091837 A JP 2024091837A JP 2024091837 A JP2024091837 A JP 2024091837A JP 2024113096 A5 JP2024113096 A5 JP 2024113096A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
use according
weight
rpl554
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024091837A
Other languages
English (en)
Japanese (ja)
Other versions
JP7836853B2 (ja
JP2024113096A (ja
Filing date
Publication date
Priority claimed from GB1816447.5A external-priority patent/GB2578093B/en
Application filed filed Critical
Publication of JP2024113096A publication Critical patent/JP2024113096A/ja
Publication of JP2024113096A5 publication Critical patent/JP2024113096A5/ja
Application granted granted Critical
Publication of JP7836853B2 publication Critical patent/JP7836853B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024091837A 2018-10-09 2024-06-05 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物 Active JP7836853B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1816447.5 2018-10-09
GB1816447.5A GB2578093B (en) 2018-10-09 2018-10-09 Liquid pharmaceutical composition comprising RPL554 and HFA-134A
PCT/GB2019/052863 WO2020074894A1 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
JP2021517866A JP7578587B2 (ja) 2018-10-09 2019-10-09 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021517866A Division JP7578587B2 (ja) 2018-10-09 2019-10-09 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物

Publications (3)

Publication Number Publication Date
JP2024113096A JP2024113096A (ja) 2024-08-21
JP2024113096A5 true JP2024113096A5 (https=) 2025-04-03
JP7836853B2 JP7836853B2 (ja) 2026-03-27

Family

ID=64394831

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517866A Active JP7578587B2 (ja) 2018-10-09 2019-10-09 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物
JP2024091837A Active JP7836853B2 (ja) 2018-10-09 2024-06-05 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021517866A Active JP7578587B2 (ja) 2018-10-09 2019-10-09 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物

Country Status (27)

Country Link
US (2) US20210379053A1 (https=)
EP (2) EP3820446B1 (https=)
JP (2) JP7578587B2 (https=)
KR (1) KR20210073532A (https=)
CN (1) CN112912064B (https=)
AU (1) AU2019358585B2 (https=)
BR (1) BR112021006712A2 (https=)
CA (1) CA3113167A1 (https=)
CY (1) CY1124943T1 (https=)
DK (1) DK3820446T3 (https=)
ES (1) ES2899744T3 (https=)
GB (1) GB2578093B (https=)
HR (1) HRP20220053T1 (https=)
HU (1) HUE057780T2 (https=)
IL (1) IL282032B1 (https=)
LT (1) LT3820446T (https=)
MX (2) MX2021003599A (https=)
MY (1) MY207302A (https=)
PH (1) PH12021550767A1 (https=)
PL (1) PL3820446T3 (https=)
PT (1) PT3820446T (https=)
RS (1) RS62775B1 (https=)
SG (1) SG11202102567UA (https=)
SI (1) SI3820446T1 (https=)
SM (1) SMT202200044T1 (https=)
WO (1) WO2020074894A1 (https=)
ZA (1) ZA202102039B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3142701T3 (en) 2014-05-12 2018-08-13 Verona Pharma Plc New treatment
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201916915D0 (en) 2019-11-20 2020-01-01 Amr Centre Ltd Compounds
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2024088364A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种包含异喹啉酮类化合物的药物组合物及其制备方法
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208310T3 (es) 1999-03-31 2004-06-16 Vernalis Limited Derivados de pirimido(6,1-a) isoquinolin-4-ona.
PH12013500261A1 (en) * 2010-08-09 2013-03-04 Verona Pharma Plc Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound
EP2819645A2 (en) * 2012-02-28 2015-01-07 Iceutica Holdings Inc. Bvi Inhalable pharmaceutical compositions
EP2968313B1 (en) 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
DK3142701T3 (en) * 2014-05-12 2018-08-13 Verona Pharma Plc New treatment
CN110051627A (zh) * 2014-09-15 2019-07-26 维罗纳制药公司 包含rpl554的液体吸入制剂
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Similar Documents

Publication Publication Date Title
JP2024113096A5 (https=)
JP3056784B2 (ja) エアゾール医薬製剤
US20090298802A1 (en) Pharmaceutical Compositions
CZ2000950A3 (cs) Použití kombinace formoterolu a budesonidu k výrobě farmaceutického prostředku k léčbě chronické obstrukční plicní choroby
HRP20220053T1 (hr) Farmaceutski sastavi koji sadrže rpl554 u hfa-134a za primjenu inhalacijom
NZ538493A (en) Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
JP2774379B2 (ja) 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途
MX2012011179A (es) Composicion farmaceutica en polvo para inhalacion.
JP2019534270A5 (https=)
Kaur et al. Advanced aerosol delivery devices for potential cure of acute and chronic diseases
JP2021522161A5 (https=)
US6187765B1 (en) Mometasone furoate suspensions for nebulization
EP1033991B1 (en) Mometasone furoate suspensions for nebulization
ES3037198T3 (en) Combination therapy for inhalation administration
WO2015027848A1 (zh) 含有帕拉米韦和/或其衍生物制剂的给药方法
WO2012042197A2 (en) Low dose pharmaceutical composition
Dongare et al. An overview of recently published patents on pulmonary drug delivery devices
JP2014527056A (ja) 呼吸器疾患を治療するための定量噴霧式吸入剤を調製する方法
WO2010146394A1 (en) Theobromine for the treatment of cough
MX2013004030A (es) Composicion farmaceutica a base de denufosol para tratar fibrosis quistica.
MXPA05001901A (es) Composiciones para inhalacion con altas proporciones de medicamento.
JPWO2020074894A5 (https=)
MXPA06008240A (es) Metodos de tratamiento.
ES2612257T3 (es) Formulación de suspensión mejorada de dipropionato de beclometasona para administración mediante inhalación
JPWO2019204583A5 (https=)